EAN 2022 | Blood-based biomarkers are one of the greatest developments in neuroimmunology

Neuroimmunology is a rapidly progressing field, with studies of basic science, disease models, and neurological immune therapy driving key developments in our understanding of not only neuroimmunological disease, but also the immune/inflammatory mechanisms underlying neurological and psychiatric disease manifestations. Stefan Bittner, MD, Johannes Gutenberg-University, Mainz, Germany, discusses the development of novel blood-based biomarkers as the hottest topic in clinical neuroimmunology. Neurofilament light (NfL) is a measure of neuronal damage and has been widely shown to provide valuable information in several neurological diseases, notably multiple sclerosis. Prof. Bittner highlights NfL as a putative first-in-class liquid biomarker on its way into clinical practice. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.